Immatics (IMTX) Revenue & Revenue Breakdown
Immatics Revenue Highlights
Latest Revenue (Y)
$54.00M
Latest Revenue (Q)
$30.45M
Immatics Revenue by Period
Immatics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $54.00M | -68.76% |
| 2022-12-31 | $172.83M | 397.17% |
| 2021-12-31 | $34.76M | 11.23% |
| 2020-12-31 | $31.25M | 69.40% |
| 2019-12-31 | $18.45M | 389.36% |
| 2018-12-31 | $3.77M | - |
Immatics generated $54.00M in revenue during NA 2023, up -68.76% compared to the previous quarter, and up 1432.28% compared to the same period a year ago.
Immatics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $30.45M | 91.24% |
| 2023-12-31 | $15.92M | 168.66% |
| 2023-09-30 | $5.93M | -73.49% |
| 2023-06-30 | $22.35M | 128.20% |
| 2023-03-31 | $9.80M | -73.98% |
| 2022-12-31 | $37.65M | 149.99% |
| 2022-09-30 | $15.06M | -12.52% |
| 2022-06-30 | $17.21M | -83.27% |
| 2022-03-31 | $102.91M | 554.33% |
| 2021-12-31 | $15.73M | 144.09% |
| 2021-09-30 | $6.44M | 24.17% |
| 2021-06-30 | $5.19M | -29.91% |
| 2021-03-31 | $7.40M | -21.63% |
| 2020-12-31 | $9.45M | 20.01% |
| 2020-09-30 | $7.87M | 14.14% |
| 2020-06-30 | $6.90M | -2.05% |
| 2020-03-31 | $7.04M | 60.58% |
| 2019-12-31 | $4.38M | -13.29% |
| 2019-09-30 | $5.06M | -6.09% |
| 2019-06-30 | $5.38M | 16.73% |
| 2019-03-31 | $4.61M | 389.36% |
| 2018-12-31 | $942.50K | - |
| 2018-09-30 | $942.50K | - |
| 2018-06-30 | $942.50K | - |
| 2018-03-31 | $942.50K | - |
Immatics generated $30.45M in revenue during Q1 2024, up 91.24% compared to the previous quarter, and up 80.87% compared to the same period a year ago.
Immatics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| HRMY | Harmony Biosciences | $582.02M | $172.81M |
| IMTX | Immatics | $54.00M | $30.45M |
| MRUS | Merus | $43.95M | $7.33M |
| FENC | Fennec Pharmaceuticals | $21.64M | $25.26M |
| JANX | Janux Therapeutics | $8.08M | $1.25M |
| KRON | Kronos Bio | $6.29M | $2.69M |
| CRNX | Crinetics Pharmaceuticals | $4.01M | $640.00K |
| INBX | Inhibrx | $1.80M | - |
| KROS | Keros Therapeutics | $151.00K | $83.00K |
| LYEL | Lyell Immunopharma | $130.00K | $3.00K |
| ALXO | ALX Oncology | - | - |
| BCAB | BioAtla | - | - |
| AVTE | Aerovate Therapeutics | - | - |
| REPL | Replimune Group | - | - |
| SNDX | Syndax Pharmaceuticals | - | $3.50M |
| MLYS | Mineralys Therapeutics | - | - |
| EWTX | Edgewise Therapeutics | - | - |
IMTX Revenue FAQ
What is Immatics’s yearly revenue?
Immatics's yearly revenue for 2023 was $54M, representing a decrease of -68.76% compared to 2022. The company's yearly revenue for 2022 was $172.83M, representing an increase of 397.17% compared to 2021. IMTX's yearly revenue for 2021 was $34.76M, representing an increase of 11.23% compared to 2020.
What is Immatics’s quarterly revenue?
Immatics's quarterly revenue for Q1 2024 was $30.45M, a 91.24% increase from the previous quarter (Q4 2023), and a 210.81% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $15.92M, a 168.66% increase from the previous quarter (Q3 2023), and a -57.71% decrease year-over-year (Q4 2022). IMTX's quarterly revenue for Q3 2023 was $5.93M, a -73.49% decrease from the previous quarter (Q2 2023), and a -60.65% decrease year-over-year (Q3 2022).
What is Immatics’s revenue growth rate?
Immatics's revenue growth rate for the last 3 years (2021-2023) was 55.33%, and for the last 5 years (2019-2023) was 192.68%.